Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.48 |
| ▸ | IL1B | P01584 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145891 | 1.00 | CHRNA7 (0.48) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1146047 | 0.90 | CHRNA7 (0.48) | CHRNA7IL1BNLRP3CHRNB2CHRNB4 | |
| SCHEMBL1146048 | 0.90 | CHRNA7 (0.48) | CHRNA7IL1BNLRP3CHRNB2CHRNB4 | |
| SCHEMBL1146543 | 0.90 | CHRNA7 (0.49) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1146544 | 0.90 | CHRNA7 (0.49) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1146424 | 0.87 | CHRNA7 (0.52) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1146427 | 0.87 | CHRNA7 (0.52) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1146192 | 0.86 | CHRNA7 (0.48) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1146195 | 0.86 | CHRNA7 (0.48) | CHRNA7IL1BNLRP3CHRM2CHRM1 | |
| SCHEMBL1146295 | 0.85 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475811-B2 | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-8933090-B2 | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2015-01-13 | — | — | US | disclosed |
| EP-2336129-A1 | 1-aza-bicyclo[3.3.1]nonanes | Novartis AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20110034475-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG | 2011-02-10 | — | — | US | disclosed |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | CBR3, CBR1, HCAR3 | CHRNA7 119/4885IL1B 4589/4885NLRP3 4610/4885 |
| US-20110034475-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | CBR3, CBR1, HRH4 | CHRNA7 208/4885IL1B 4662/4885NLRP3 4715/4885 |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | CBR3, CBR1, ADCY3 | CHRNA7 228/4885IL1B 4426/4885NLRP3 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.